Efficacy and Safety of Benvitimod Cream in the Retreatment of Mild to Moderate Psoriasis
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a retreatment, multicenter, randomized, double-blind, placebo-controlled clinical
study to evaluate the safety and efficacy of Benvitimod cream, 1% twice daily for the
retreatment of mild to moderate stable psoriasis vulgaris in adults. Approximately 390
participants with mild to moderate stable psoriasis vulgaris will be enrolled and randomly
divided into two groups in a 2:1 ratio. They will use either the Benvitimod cream or placebo
at the skin with psoriasis vulgaris for 12 weeks.